| Trial ID: | L0611 |
| Source ID: | NCT02443116
|
| Associated Drug: |
NGM282
|
| Title: |
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administere
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Steatohepatitis (NASH)
|
| Interventions: |
Biological: NGM282;Other: Placebo
|
| Outcome Measures: |
Change in absolute liver fat content as measured by MRI from Baseline to Week 24Change in percentage liver fat content as measure by MRI from Baseline to Week 24
|
| Sponsor/Collaborators: |
NGM Biopharmaceuticals, Inc
|
| Gender: |
All
|
| Age: |
18 Years75 Years
|
| Phases: |
Phase 2
|
| Enrollment: |
254
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
|
| Start Date: |
11/05/2015
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
United States;Australia;Puerto Rico;Australia;Puerto Rico;United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02443116
|
